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Abstract  
 
An in vitro biorelevant transfer (BioGIT) system was assessed for its ability to mimic recently 
reported albendazole concentrations in human upper small intestine after administration of 
free base suspensions to fasted adults in absence and in presence of supersaturation 
promoting excipients (hydroxypropylmethylcellulose and lipidic self-emulsifying vehicles). 
The in vitro method was then used to evaluate the likely impact of using the sulfate salt on 
albendazole concentrations in upper small intestine. In addition, BioGIT data were compared 
with equilibrium solubility data of the salt and the free base in human aspirates and 
biorelevant media. The BioGIT system adequately mimicked the average albendazole 
gastrointestinal transfer process and in vivo concentrations in upper small intestine after 
administration of the free base suspensions to fasted adults. However, the degree of 
supersaturation seen initially in the duodenuum was greater in-vitro than in-vivo. 
Albendazole sulfate resulted in minimal increase of albendazole concentrations in the 
duodenal compartment of the BioGIT, despite improved equilibrium solubility observed in 
human aspirates and biorelevant media, indicating that the use of a salt is unlikely to lead to 
any significant oral absorption advantage for albendazole. 
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Introduction 
 
New drug candidates often have low aqueous solubility to an extent that require 
administration in enabling formulations to promote supersaturation, in order to achieve 
luminal concentrations to get most of the dose absorbed (e.g. Brouwers et al. 2009). In case 
of a poorly soluble weak base, the impact of gastrointestinal transfer in the fasted state on 
absorption rates may be substantial, because, due to the abrupt increase in pH, precipitation 
in the upper small intestine is likely. The use of supersaturation promoting formulations may 
then be required. 
 
Various methodologies have been proposed to evaluate to impact of gastrointestinal 
transfer on the performance of the dosage form and of the drug intraluminally (Kostewicz et 
al. 2014). Recently, an in vitro biorelevant gastrointestinal transfer (BioGIT) system was 
proposed for the evaluation of the impact of gastrointestinal transfer on concentrations in 
upper intestinal lumen during the first hour, after oral administration of dispersing/solution 
dosage forms of lipophilic weak bases in the fasted state (Kourentas et al. 2016). 
 
In the present investigation, the impact of excipients and of free base vs. salt on 
concentrations of lipophilic weak bases in upper small intestine was investigated with BioGIT 
by using albendazole free base [ABZ, pka 2.80 (Jung et al 1998), logP 3.46 (Rivera et al. 
2007)] as a model lipophilic weak base. There were three specific objectives of the present 
study: 
 
Firstly, to evaluate the usefulness of BioGIT in reproducing recently observed ABZ 
concentrations and supersaturation of contents of the upper small intestine of healthy 
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adults after administration of various ABZ free base suspensions in absence and in presence 
of supersaturation promoting excipients in the fasted state (Kourentas et al. submitted). 
 
Secondly, to evaluate the impact of free base vs. salt on ABZ concentrations and degrees of 
supersaturation of contents of the upper small intestine in absence and in presence of HPMC 
E5 using BioGIT. 
 
Thirdly, to compare BioGIT data with equilibrium solubility data (in human aspirates and in 
biorelevant media) in order to evaluate the impact of free base vs. salt on ABZ behaviour in 
the upper gastrointestinal lumen. 
 
Since only the free base of ABZ is commercially available, a salt had to be prepared for the 
needs of the present investigation. Although various salts of ABZ have been prepared and 
characterized in the past (Paulekuhn et al. 2013), the relatively low pKa makes ABZ salts 
sensitive to disproportionation (e.g. Stephenson et al. 2011). After considering various 
counter-ions, the sulfate salt of ABZ was selected to be used, based on its comparatively 
better crystallinity and stability characteristics. 
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Materials and Methods 
 
Materials 
 
Albendazole free base was from Sigma Aldrich (Saint Louis, U.S.A., 99% pure). Sodium 
phosphate monobasic, sodium hydroxide, sodium chloride, ammonium formate, and pepsin 
from porcine gastric mucosa (15.8% protein) were purchased from Sigma Aldrich (Saint 
Louis, U.S.A.). Acetonitrile and water (HPLC grade) as well as tetrahydrofuran and ethanol 
were also from Sigma Aldrich (Saint Louis, U.S.A.). n-butanol was purchased from Fluka (Neu-
Ulm, Germany). SIF® Powder Original was kindly donated by Biorelevant.com (Surrey, U.K.). 
Hydrochloric acid was from Panreac Co. (Barcelona, Spain). Hydroxypropylmethylcellulose E5 
was from JRS Pharma (Zacapu, Mexico). Miglyol 812N [Caprylic/Capric (C8 ?C10) 
triglycerides] was received from Sasol Germany. Cremophor RH 40 was from BASF 
(Ludwigshafen, Germany). Polysorbate 80 was from Sigma Aldrich (Saint Louis, U.S.A.). 
 
Preparation of various ABZ salts and selection of the sulfate salt 
 
Initially, the solubility of ABZ free base was assessed in tetrahydrofuran, ethanol, water, and 
n-butanol at a range of temperatures (25-80 °C). In order to obtain albendazole 
hydrochloride, albendazole sulfate and albendazole mesylate, 10, 20, 30, 40 and 50 mg of 
ABZ free base were transferred into 2 ml HPLC vials followed by the addition of 1 ml of 
solvent (tetrahydrofuran, water, ethanol or n-butanol) and the addition of an equi-molar 
amount of acid (HCl, H2SO4 or methanesulfonic acid). The vials were placed in a Crystal 16 
apparatus (Avantium Crystallization System, Amsterdam, Netherlands), temperature was 
cycled with the maximum temperature set 10°C below the solvents boiling point and the salt 
was formed at the end of the experiment. Two scale-up experiments were conducted using 
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25 ml and 50 ml of solvent, to ensure the scale-up procedure was viable. Equi-molar 
amounts of ABZ free base and the acids (HCl, H2SO4, or methanesulfonic acid) were added to 
100 ml glass beakers containing either 25 or 50 ml of solvent and the mixture heated to 10 
degrees below the boiling point of the solvent. At the elevated temperature the ABZ salt was 
completely dissolved; it was then left at room temperature to cool down and the salt 
precipitated. Residual solvent was evaporated at room temperature and the material was 
further dried at 40 °C, over 24 hours, and weighed. The formation of ABZ salts (as hydrates, 
based on Karl-Fisher titration data) was confirmed using Nuclear Marnetic Resonance, 
Differential Scanning Calorimetry (30  ? 300 °C in 10 min, Mettler Toledo DSC 822e), and 
Elemental Analysis for carbon, hydrogen and nitrogen (data on file). Based on X-ray 
diffraction data, albendazole hydrochloride was poorly crystalline (unlike with a previous 
report (Paulekuhn et al. 2013) whereas albendazole mesylate crystals and crystal stability 
characteristics varied with the solvent used for their isolation. In contrast, albendazole 
sulfate salt (ABZ sulfate) samples obtained with tetrahydrofuran and ethanol were 
concordant (some differences in peak intensities may suggest small differences in 
crystallinity). Also, based on the one-month stability data ABZ sulfate, peaks were 
concordant at two tested conditions (40 oC / 75% humidity and 50 oC / ambient humidity) 
with the initial analysis. Based on these data, ABZ sulfate obtained using tetrahydrofuran 
was selected to be used in the present investigation. 
 
Experiments with BioGIT 
 
Methodology 
 
BioGIT is an in vitro three compartment setup simulating the drug transfer from the stomach 
into the fasted upper small intestine (Kourentas et al. 2016). The initial volume of the gastric 
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compartment is 250 ml. The duodenal volume is maintained at 40 ml during the entire 
experiment. The mini - paddles in gastric and duodenal compartments rotate at 75 rpm. The 
emptying of contents of gastric compartment (on a volume basis) follows first-order kinetics 
with a half-life of 15 min. Experiments are performed using a three-channel peristaltic pump 
(Reglo ICC pump, part ISM 4308, Ismatec®) for 45 min, after the initiation of an experiment. 
Incoming flow rates are changed every 10 min and sampling is performed at midpoint 
(Kourentas et al. 2016). In this study, experiments were performed in triplicate at 37 °C. 
 
Contents of gastric compartment 
 
Two aqueous suspensions of ABZ free base were tested. For the first, 50 mg ABZ free base 
were mixed with 200 ml table water (Nera Kritis, Heraklion, Greece) under vigorous 
magnetic stirring for 5 min at room temperature. Preparation of the second suspension was 
achieved by dissolving 5 mg HPMC E5 in 200 ml table water, prior to mixing 50 mg ABZ free 
base with the aqueous HPMC E5 solution. Regardless of the presence of HPMC E5, the 
suspension was mixed with 50 ml concentrated Level III FaSSGF. The resulting 250 ml 
suspension in Level III FaSSGF (Markopoulos, Andreas et al. 2015), Susp or Susp-HPMC, was 
immediately added to the gastric compartment, and the transfer experiment was initiated. 
 
Two lipid based suspensions of ABZ free base were tested, prepared from one Type IIIA and 
one Type IV lipid based formulation (Pouton, 2006). The appropriate quantities of excipients 
were weighed into a screw cap glass bottle of 50 ml capacity, i.e. 0.4 g Miglyol 812N, 0.2 g 
Cremophor RH 40 and 0.4 g Tween 80 for Type IIIA lipid based formulation and 0.2 g 
Cremophor RH40 and 0.4 g Tween 80 for Type IV lipid based formulation (Kourentas et al. 
submitted). An accurately weighed quantity of 50 mg ABZ free base was added into the glass 
bottle. The components were mixed using a magnetic stirrer for 1 h at room temperature. 
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The lipid based formulations of ABZ free base were stored at room temperature overnight 
(Kourentas et al. submitted). Each lipid based formulation was transferred to a screw cap 
glass bottle of 250 ml capacity by rinsing the 50 ml capacity glass bottle with small amounts 
of table water (total volume of table water used for rinsing was 200 ml). The 250 ml capacity 
bottle was then vigorously stirred using a magnetic stirrer for 5 min at room temperature 
(Kourentas et al. submitted), 50 ml of concentrated Level III FaSSGF were added into the 
bottle and mixed. The resulting 250 ml suspension in Level III FaSSGF, Susp-IIIA or Susp-IV, 
was immediately added to the gastric compartment, and the experiment initiated. 
 
Assuming that resting gastric volume in the fasted state is 10 ml (Psachoulias et al. 2011; 
Vertzoni et al. 2012), volume and composition of contents in the gastric compartment when 
using ABZ free base suspensions reflected the expected composition of gastric contents after 
administration of the following suspensions to fasted adults (Kourentas et al. submitted): 
- Suspension of ABZ free base in 240 ml table water (Susp) 
- Suspension of ABZ free base in 240 ml table water in which HPMC E5 had been pre-
dissolved (Susp-HPMC) 
- Suspension of a Type IIIA lipid based formulation of ABZ free base in 240 ml table water 
(Susp-IIIA) 
- Suspension of a Type IV lipid based formulation of ABZ free base in 240 ml table water 
(Susp-IV) 
 
Two aqueous suspensions of ABZ sulfate were then tested. For the first, 50 mg ABZ 
equivalent were mixed with 200 ml table water under vigorous magnetic stirring for 5 min at 
room temperature. Preparation of the second suspension was achieved by dissolving 5 mg 
HPMC E5 in 200 ml table water, prior to mixing 50 mg ABZ equivalent with the aqueous 
HPMC E5 solution. Regardless of the presence of HPMC E5, the suspension was mixed with 
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50 ml concentrated Level III FaSSGF. The resulting 250 ml suspension in Level III FaSSGF 
(Markopoulos, Andreas et al. 2015), S-Susp or S-Susp-HPMC, was immediately added to the 
gastric compartment, and the transfer experiment was initiated. 
 
The composition of contents in the gastric compartment were designed to reflect 
intragastric conditions using the same assumptions made for the ABZ free base suspensions 
and mimicking administration of the following ABZ sulfate suspensions to fasted adults: 
-Suspension of ABZ sulfate in 240 ml table water (S-Susp) 
-Suspension of ABZ sulfate in 240 ml table water containing HPMC E5 (S-Susp-HPMC) 
 
In all experiments (with ABZ free base and with ABZ sulfate), concentrated Level III FaSSGF 
had pH 0.9 whereas concentrations of sodium chloride, pepsin, sodium taurocholate and 
phosphatidylcholine were 5-fold higher than in Level III FaSSGF pH 1.6 (Markopoulos, 
Andreas et al. 2015). 
 
Contents of duodenal compartment at time zero and contents of reservoir compartment 
 
Level II FaSSIF (Markopoulos, Andreas et al. 2015) was employed in the duodenal 
compartment in order to simulate the fasted state conditions in upper small intestine. A 
series of phosphate buffer solutions containing sodium chloride, bile salt and lecithin were 
employed in the reservoir compartment so that the composition of contents in the duodenal 
compartment (pH, buffer capacity, osmolality, bile salt and lecithin concentration) remains 
unaltered during an experiment (Kourentas et al. 2016). 
 
Sample treatment 
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Upon collection, each sample from the duodenal compartment was divided into two parts:  
i) The first part was immediately filtered through regenerated cellulose filters (Titan 3, 17 
ŵŵ ? ? ? ? ?ʅŵ ?^hE^Zŝ ?ZŽĐŬǁŽŽĚ ?h ?^ ? ? )ĂŶĚƚŚĞĨŝůƚƌĂƚĞǁĂƐĚ ǀŝĚĞĚŝŶƚǁo portions: 
- The first, after immediate dilution with mobile phase (so that precipitation 
during subsequent handling is avoided), was used for measuring ABZ 
concentration. 
- The second portion was incubated (37 °C, 75 oscillations/min, model Unitronic 
OR, j.p. Selecta, s.a., Barcelona, Spain) in presence of excess of ABZ free base or 
ABZ sulfate solid material for 16 hours and, after filtration through a 
ƌĞŐĞŶĞƌĂƚĞĚĐĞůůƵůŽƐĞ ? ? ? ?ʅŵĨŝůƚĞƌ ?ĞƋƵŝůŝďƌŝƵŵƐŽůƵďŝůŝƚǇǁĂƐĚĞƚĞƌŵŝŶĞĚ ?dŚĞ
duration of incubation for achieving equilibration had been evaluated with 
preliminary experiments. 
Adsorption of ABZ on to the regenerated cellulose filter had been evaluated and found to be 
negligible. 
ii) The second part was used for measuring total ABZ amount (solid and dissolved drug) per 
volume, after appropriate dilution with mobile phase. 
 
Equilibrium solubility of ABZ free base and ABZ sulfate in biorelevant media and in humans 
aspirates 
 
The solubility of ABZ free base and ABZ sulfate were measured in Level III FaSSGF, in Level II 
FaSSIF (Markopoulos, Andreas et al. 2015) and in human aspirates collected from the 
stomach and from the upper small intestine in the fasted state. Human aspirates had been 
collected from healthy fasted adults (Petrakis et al. 2014) and pooled after one freeze-thaw 
cycle. The pH after pooling was 1.6 for the gastric pooled sample (human gastric fluid, HGF) 
and 7.4 for intestinal pooled sample (human intestinal fluid, HIF). An excess amount of ABZ 
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free base or ABZ sulfate solid material was added to glass vials containing the appropriate 
medium. The vials were incubated at 37 °C (75 oscillations/min) until equilibrium was 
reached. Equilibration times in human aspirates and in biorelevant media were evaluated 
with preliminary experiments at 4h, 16h and 24h, after initiation of the incubation. For each 
medium, concentrations were measured to be identical at all sampling times. For practical 
reasons solubility values were measured at 16h in all media. At equilibrium, samples from 
ďŝŽƌĞůĞǀĂŶƚŵĞĚŝĂǁĞƌĞĨŝůƚĞƌĞĚƚŚƌŽƵŐŚ ? ? ? ?ʅŵƌĞŐĞŶƌĂƚĞĚĐĞůůƵůŽƐĞĨŝůƚĞƌƐǁŚĞƌĞĂƐ,'&
and HIF samples were centrifuged (11800 g, 37 °C, 10 min). Filtrates and supernatants were 
diluted with equal volume of mobile phase and samples were subjected to HPLC analysis. All 
measurements were performed in triplicate. The adequacy of filtration vs. centrifugation to 
separate dissolved from undissolved material had been evaluated with preliminary 
experiments (Kourentas et al. submitted). 
 
ABZ assay 
 
ABZ assay was performed on a Spectra HPLC system consisting of a P1000 pump, an AS1000 
autosampler, a UV2000 detector, and an SN4000 controller which was programmed by the 
Chromquest® software (version 2.51, Thermoquest Inc., USA). Analysis of drug content 
ŝŶǀŽůǀĞĚƚŚĞƵƐĞŽĨĂ&ŽƌƚŝƐ ? ?ĐŽůƵŵŶ ? ?ʅŵ ? ? ? ?A? ?ŵŵ )ĞƋƵŝƉƉĞĚǁŝƚŚĂ^ ? ? ? ?ʅŵ ?
10×4.6 mm) pre-column. The mobile phase consisted of ammonium formate (50 mM): 
acetonitrile 50:50 v/v, the flow rate was 0.5 ml/min, the wavelength was set at 292 nm and 
ƚŚĞŝŶũĞĐƚŝŽŶǀŽůƵŵĞǁĂƐ ? ?ʅů ?/ŶĂůůĐĂƐĞƐ ?ƌĞƐƵůƚƐĂƌĞĞǆƉƌĞƐƐĞĚĂƐĨƌĞĞďĂƐĞ ?
Quantification limit was 10 ng/ml. 
 
Data Analysis 
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Raw data are presented as Box-Whisker plots showing the median value, the 10th, 25th, 75th, 
and 90th percentiles, and the individual outlying data points. 
Supersaturation in duodenal compartment was evaluated by estimating the Degree of 
Supersaturation, DS: 
ilitySomEquilibriu
ionConcentrat
DS
lub 
      (Eq. 1) 
DS>1 indicates supersaturation, DS=1 indicates saturation, and DS<1 indicates unsaturated 
solution. 
 
One-sample t ?test (Sigmaplot 11.0, Systat Software, Inc., San Jose, California, USA) was 
applied for evaluating whether a sample mean DS value comes from a population with mean 
of 1. Differences between solubility in human fluids and biorelevant media and between ABZ 
free base and ABZ sulfate were evaluated with unpaired t-test (Sigmaplot 11.0, Systat 
Software, Inc., San Jose, California, USA). Maximum type I error had been set at 0.05, in all 
cases. 
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Results and Discussion 
 
BioGIT data vs. data in the upper small intestine after administration of ABZ free base 
suspensions 
 
The total ABZ amount per volume in the duodenal compartment matched the average 
luminal data during the first 50 min of gastric emptying of Susp, Susp-HPMC, Susp-IIIA and 
Susp-IV (Figure 1). The BioGIT data are consistent with the lower total ABZ amount per 
volume in upper small intestine observed after administration of Susp and Susp-HPMC than 
after administration of Susp-IIIA or Susp-IV to fasted adults (diamonds and boxes in Figures 
1a and 1b vs. diamonds and boxes in Figures 1c and 1d). As reported recently (Kourentas et 
al. submitted), total ABZ amount per volume in upper small intestine, after administration of 
Susp-IIIA and Susp-IV are in line with first-order gastric emptying kinetics and half-life of 15 
minutes (Figure 1, continuous lines). Lower total ABZ amount per volume, after Susp or 
Susp-HPMC could be attributed to the slower emptying of Susp and Susp-HPMC, due to 
floating and/or adhesion of aggregates on to the walls of the gastric compartment (visually 
observed in this study) and in stomach (Kourentas et al. submitted). 
 
When using Susp or Susp-HPMC, ABZ concentrations in the duodenal compartment early, i.e. 
about 5 minutes, after initiation of the experiment were somewhat higher than the average 
concentrations in the upper small intestine (Figures 2a and 2b). This may be attributed to 
the pH of contents in the gastric compartment (FaSSGF, pH 1.6) which reflects the average 
pH in the stomach during the gastric emptying of glass of water in the fasted state, i.e. it is 
lower than the pH expected to be in stomach early after administration of a glass of water 
(about 2.5, e.g. Kalantzi et al. 2006). The lower than physiological pH at early times after 
initiation of the experiment accelerates ABZ free base dissolution and, therefore, 
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concentrations in gastric and, subsequently, in duodenal compartment are increased, 
compared with concentrations in the human upper gastrointestinal lumen at early times, 
after administration. When using Susp-IIIA or Susp-IV, the discrepancy between in vitro and 
luminal concentrations at early times was not apparent (Figures 2c and 2d). The fact that 
ABZ concentration in Susp-IIIA and in Susp-IV administered to adults was 9 and 6 times, 
respectively, higher than ABZ concentration in the administered Susp or Susp-HPMC 
(Kourentas et al. submitted) could be a reason for the similarity of in vitro with luminal data 
of Susp-IIIA and of Susp-IV at early times. 
 
In all cases, ABZ concentrations in the duodenal compartment after about 5 minutes post 
experiment start generally matched the average data in upper small intestine during the first 
50 minutes, after administration of all four tested ABZ free base suspensions to fasted adults 
(Figure 2). 
 
Solubility values in duodenal compartment of BioGIT were in line with previously measured 
values in the lumen of upper small intestine of healthy adults (Figure 3). Occasionally, 
limited underestimation was observed, primarily in the case of Susp-IIIA (Figure 3c). 
Contents of the duodenal compartment of BioGIT were significantly supersaturated in case 
of Susp, Susp-HPMC, and Susp-IIIA at all sampling times but one, after initiation of the 
experiment (Table 1). In case of Susp-IV, significant supersaturation was observed only 
occasionally (Table 1). Recently reported data from the upper small intestine of healthy 
adults suggest that significant supersaturation occurs only in case of Susp-HPMC, Susp-IIIA, 
and Susp-IV and at specific times post administration (Kourentas et al. submitted). The 
discrepancy between in vitro and luminal supersaturation could be attributed to the higher 
concentrations in BioGIT at early times (diamonds vs. boxes in Figures 2a, 2b, and 2c), the 
lower solubility in the duodenal compartment measured occasionally (Figure 3c), and the 
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high variability of luminal data which led to high average degrees of supersaturation but of 
borderline statistical significance (Kourentas et al. submitted). Overall, the BioGIT data, 
consistent with the human data (Kourentas et al. submitted) indicates that the lipid based 
formulations may be slightly less effective that formulations containing HPMC E5 in 
maintaining supersaturation in upper small intestine (Table 1). 
 
BioGIT data using ABZ free base and ABZ sulfate suspensions 
 
Total ABZ amount per volume in the duodenal compartment of BioGIT did not change 
substantially when S-Susp or S-Susp-HPMC was used in the gastric compartment (Figure 4a 
vs. Figure 1a and 1b). ABZ concentrations in the duodenal compartment also remained 
substantially unaffected, apart from at 5 minutes; when using S-Susp-HPMC concentration at 
5 min was almost doubled, compared with the concentration measured when using Susp-
HPMC (Figure 4b vs. Figure 2b). 
 
Since solubility of ABZ sulfate was not affected by the presence of HPMC E5 (Figure 4b), the 
higher supersaturation when using S-Susp-HPMC could be attributed to the increased 
concentrations in presence of HPMC E5, especially at early times, after initiation of the 
experiment (Figure 4b). Although mean values of the degree of supersaturation were higher 
with S-Susp-HPMC than with S-Susp (Table 2), values were smaller than those estimated 
using Susp-HPMC and Susp, respectively (Table 2 vs. Table 1). 
 
Regardless of the presence of HPMC E5, BioGIT data suggest that, compared with ABZ free 
base, ABZ sulfate will not lead to significantly more drug available for absorption. This is in 
line with literature data suggesting that usefulness of salts in increasing the absorption of 
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lipophilic weak bases has not been well documented in humans (Verbeeck et al. 2006) and 
may be overestimated (Erceg et al. 2012; Dimopoulou et al. in press). 
 
ȵquilibrium solubility data vs. BioGIT data for evaluating the impact of free base vs. salt on 
ABZ concentrations in upper small intestine 
 
ABZ free base equilibrium solubility in Level III FaSSGF (mean: 128 Pg/ml, Figure 5a) is in line 
with its pH - solubility profile (Paulekuhn et al. 2013). Solubilities in Level III FaSSGF and in 
HGF as well solubilities in Level II FaSSIF and in HIF are significantly higher when ABZ sulfate 
is used; compared with mean solubility of ABZ free base, mean solubility of ABZ sulfate is 3.8 
times higher both in Level III FaSSGF and in HGF (Figure 5a). Similarly, compared with data 
when ABZ free base was used, solubility in equilibrium with ABZ sulfate is 2.3 and 3.1 times 
higher in Level II FaSSIF and in HIF, respectively (Figure 5b). 
 
Although ABZ sulfate is more soluble in contents and in simulated contents of upper 
gastrointestinal lumen (Figure 5), concentrations in duodenal compartment of BioGIT when 
using Susp and when using S-Susp were similar (Figure 2a vs. Figure 4b). 
 
18 
 
Concluding remarks 
 
BioGIT was demonstrated to be a useful tool for mimicking the average gastrointestinal 
transfer process and concentrations in upper small intestine observed after administration 
of various ABZ free base suspensions to fasted adults. However, compared with luminal 
data, a greater extent of supersaturation in the duodenal compartment in the BioGIT was 
typically observed. 
 
BioGIT data indicate that ABZ sulfate, despite its improved equilibrium solubility in contents 
of stomach and upper small intestine, leads to only a minimal, transient increase of 
concentrations of ABZ in upper small intestine (only in the first 10 minutes after 
administration and enhanced by the presence of HPMC E5). These data suggest that 
equilibrium solubility data should be used to evaluate the luminal concentrations cautiously 
in situations where supersaturation and precipitation is likely to occur. 
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Table 1: Mean±SD (n=3) values for the Degree of Supersaturation (DS) in samples collected 
from the duodenal compartment of BioGIT at times corresponding to specific time intervals, 
after initiation of the experiment when using various ABZ free base suspensions in the 
gastric compartment. 
Time interval 
(min) 
Susp Susp-HPMC Susp-IIIA Susp-IV 
0-10 4.66±0.52* 5.52±0.87* 3.11±0.40* 1.25±0.05* 
10-20 4.93±0.59* 5.90±0.44* 3.84±0.57* 1.29±0.22 
20-30 5.07±0.66* 5.93±0.76* 4.08±0.80* 1.22±0.11 
30-40 5.06±0.38* 4.09±0.85* 3.30±0.80 1.38±0.15* 
40-50 4.15±0.40* 3.81±0.29* 3.16±0.48* 1.21±0.11 
 
*Statistically different from 1 at the 0.05 level of significance 
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Table 2: Mean±SD, (n=3) values for the Degree of Supersaturation (DS) in samples collected 
from the duodenal compartment of BioGIT at times corresponding to specific time intervals, 
after initiation of the experiment when using various ABZ sulfate suspensions in the gastric 
compartment*. 
Time interval 
(min) 
S-Susp S-Susp-HPMC 
0-10 2.99±0.08 4.90±0.07 
10-20 1.77±0.06 2.39±0.15 
20-30 1.89±0.14 2.89±0.07 
30-40 2.34±0.05 2.51±0.35 
40-50 2.20±0.04 2.25±0.17 
 
*All mean values were statistically different from 1 at the 0.05 level of significance 
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Figure captions 
 
Figure 1 
Mean±SD (n=3) values (diamonds) for the total ABZ amount per volume in the duodenal 
compartment vs. time after initiation of the experiment with BioGIT when using Susp (a), 
Susp-HPMC (b), Susp-IIIA (c) and Susp-IV (d) in the gastric compartment. For comparative 
purposes, values estimated using the transfer model equation (continuous lines, Kourentas 
et al. 2016), and recently reported total ABZ amount per volume in the contents of upper 
small intestine, after administration of the corresponding suspensions to healthy adults are 
also presented (box-whisker plots with dotted lines indicating the means, Kourentas et al. 
submitted). 
 
Figure 2 
Mean±SD (n=3) values (diamonds) for ABZ concentration in the duodenal compartment vs. 
time after initiation of the experiment with BioGIT when using Susp (a), Susp-HPMC (b), 
Susp-IIIA (c) and Susp-IV (d) in the gastric compartment. For comparative purposes, recently 
reported ABZ concentrations in the contents of upper small intestine of healthy adults, after 
administration of the corresponding suspensions are also presented (box-whisker plots with 
dotted lines indicating the means, Kourentas et al. submitted). 
 
Figure 3 
Mean±SD (n=3) values (triangles) for ABZ equilibrium solubility in the duodenal 
compartment at various times after the initiation of the experiment with BioGIT using Susp 
(a), Susp-HPMC (b), Susp-IIIA (c) and Susp-IV (d) in the gastric compartment. For comparative 
purposes, recently reported ABZ equilibrium solubilities measured in the contents of upper 
small intestine of healthy adults, after administration of the corresponding suspensions are 
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also presented (box-whisker plots with dotted lines indicating the means, Kourentas et al. 
submitted). 
 
Figure 4 
(a) Mean±SD (n=3) values for total ABZ amount per volume in the duodenal compartment of 
BioGIT; (b) Mean±SD (n=3) values for ABZ concentrations in duodenal compartment of 
BioGIT (symbols) and mean (n=3) values for equilibrium solubility (lines). 
Key: S-Susp, squares and continuous line; S-Susp-HPMC, triangles and dotted line. 
 
Figure 5 
Mean+SD (n=3) values for equilibrium solubility in (a) HGF and Level III FaSSGF, and (b) HIF 
and Level II FaSSIF. Key: ABZ free base, grey bars; ABZ sulfate, white bars. 
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Figure 4  
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Figure 5 
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